Literature DB >> 17145944

Evidence for an intramacrophage growth phase of Mycobacterium ulcerans.

Egídio Torrado1, Alexandra G Fraga, António G Castro, Pieter Stragier, Wayne M Meyers, Françoise Portaels, Manuel T Silva, Jorge Pedrosa.   

Abstract

Mycobacterium ulcerans is the etiologic agent of Buruli ulcer (BU), an emerging tropical skin disease. Virulent M. ulcerans secretes mycolactone, a cytotoxic exotoxin with a key pathogenic role. M. ulcerans in biopsy specimens has been described as an extracellular bacillus. In vitro assays have suggested a mycolactone-induced inhibition of M. ulcerans uptake by macrophages in which its proliferation has not been demonstrated. Therefore, and uniquely for a mycobacterium, M. ulcerans has been classified as an extracellular pathogen. In specimens from patients and in mouse footpad lesions, extracellular bacilli were concentrated in central necrotic acellular areas; however, we found bacilli within macrophages in surrounding inflammatory infiltrates. We demonstrated that mycolactone-producing M. ulcerans isolates are efficiently phagocytosed by murine macrophages, indicating that the extracellular location of M. ulcerans is not a result of inhibition of phagocytosis. Additionally, we found that M. ulcerans multiplies inside cultured mouse macrophages when low multiplicities of infection are used to prevent early mycolactone-associated cytotoxicity. Following the proliferation phase within macrophages, M. ulcerans induces the lysis of the infected host cells, becoming extracellular. Our data show that M. ulcerans, like M. tuberculosis, is an intracellular parasite with phases of intramacrophage and extracellular multiplication. The occurrence of an intramacrophage phase is in accordance with the development of cell-mediated and delayed-type hypersensitivity responses in BU patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17145944      PMCID: PMC1828495          DOI: 10.1128/IAI.00889-06

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  71 in total

1.  Mycolactone: a polyketide toxin from Mycobacterium ulcerans required for virulence.

Authors:  K M George; D Chatterjee; G Gunawardana; D Welty; J Hayman; R Lee; P L Small
Journal:  Science       Date:  1999-02-05       Impact factor: 47.728

2.  Expression of virulence of Mycobacterium tuberculosis within human monocytes: virulence correlates with intracellular growth and induction of tumor necrosis factor alpha but not with evasion of lymphocyte-dependent monocyte effector functions.

Authors:  R F Silver; Q Li; J J Ellner
Journal:  Infect Immun       Date:  1998-03       Impact factor: 3.441

3.  The histopathologic spectrum in Mycobacterium marinum infection.

Authors:  W D Travis; L B Travis; G D Roberts; D W Su; L W Weiland
Journal:  Arch Pathol Lab Med       Date:  1985-12       Impact factor: 5.534

Review 4.  Cell death: the significance of apoptosis.

Authors:  A H Wyllie; J F Kerr; A R Currie
Journal:  Int Rev Cytol       Date:  1980

5.  Ulcerative cutaneous mycobacteriosis due to Mycobacterium ulcerans: report of two Mexican cases.

Authors:  Josefa Novales-Santa Coloma; Gisela Navarrete-Franco; Pedro Iribe; Larissa Dorina López-Cepeda
Journal:  Int J Lepr Other Mycobact Dis       Date:  2005-03

6.  In vivo killing and degradation of Mycobacterium aurum within mouse peritoneal macrophages.

Authors:  M T Silva; R Appelberg; M N Silva; P M Macedo
Journal:  Infect Immun       Date:  1987-09       Impact factor: 3.441

7.  Intracellular growth and cytotoxicity of Mycobacterium haemophilum in a human epithelial cell line (Hec-1-B).

Authors:  L J Fischer; F D Quinn; E H White; C H King
Journal:  Infect Immun       Date:  1996-01       Impact factor: 3.441

8.  The production and preliminary investigation of Burulin, a new skin test reagent for Mycobacterium ulcerans infection.

Authors:  J L Stanford; W D Revill; W J Gunthorpe; J M Grange
Journal:  J Hyg (Lond)       Date:  1975-02

9.  Response in the hindfoot pad and popliteal lymph node of C57BL mice to infection with Mycobacterium marinum.

Authors:  N Mor; I Lutsky; L Levy
Journal:  Isr J Med Sci       Date:  1981-04

10.  Host and bacterial factors control the Mycobacterium avium-induced chronic peritoneal granulocytosis in mice.

Authors:  R Appelberg; J M Pedrosa; M T Silva
Journal:  Clin Exp Immunol       Date:  1991-02       Impact factor: 4.330

View more
  44 in total

1.  Chemotherapy-associated changes of histopathological features of Mycobacterium ulcerans lesions in a Buruli ulcer mouse model.

Authors:  Marie-Thérèse Ruf; Daniela Schütte; Aurélie Chauffour; Vincent Jarlier; Baohong Ji; Gerd Pluschke
Journal:  Antimicrob Agents Chemother       Date:  2011-12-05       Impact factor: 5.191

2.  Mycobacterium ulcerans triggers T-cell immunity followed by local and regional but not systemic immunosuppression.

Authors:  Alexandra G Fraga; Andrea Cruz; Teresa G Martins; Egídio Torrado; Margarida Saraiva; Daniela R Pereira; Wayne M Meyers; Françoise Portaels; Manuel T Silva; António G Castro; Jorge Pedrosa
Journal:  Infect Immun       Date:  2010-10-25       Impact factor: 3.441

Review 3.  Buruli Ulcer, a Prototype for Ecosystem-Related Infection, Caused by Mycobacterium ulcerans.

Authors:  Dezemon Zingue; Amar Bouam; Roger B D Tian; Michel Drancourt
Journal:  Clin Microbiol Rev       Date:  2017-12-13       Impact factor: 26.132

4.  Pharmacokinetics of rifampin and clarithromycin in patients treated for Mycobacterium ulcerans infection.

Authors:  J W C Alffenaar; W A Nienhuis; F de Velde; A T Zuur; A M A Wessels; D Almeida; J Grosset; O Adjei; D R A Uges; T S van der Werf
Journal:  Antimicrob Agents Chemother       Date:  2010-06-28       Impact factor: 5.191

5.  Clinical efficacy of combination of rifampin and streptomycin for treatment of Mycobacterium ulcerans disease.

Authors:  Fred Stephen Sarfo; Richard Phillips; Kingsley Asiedu; Edwin Ampadu; Nana Bobi; E Adentwe; Awuli Lartey; Ishmael Tetteh; M Wansbrough-Jones
Journal:  Antimicrob Agents Chemother       Date:  2010-06-21       Impact factor: 5.191

6.  Mycobacterium liflandii outbreak in a research colony of Xenopus (Silurana) tropicalis frogs.

Authors:  J J Fremont-Rahl; C Ek; H R Williamson; P L C Small; J G Fox; S Muthupalani
Journal:  Vet Pathol       Date:  2010-11-29       Impact factor: 2.221

7.  Challenges Associated with Management of Buruli Ulcer/Human Immunodeficiency Virus Coinfection in a Treatment Center in Ghana: A Case Series Study.

Authors:  Joseph Tuffour; Evelyn Owusu-Mireku; Marie-Therese Ruf; Samuel Aboagye; Grace Kpeli; Victor Akuoku; Janet Pereko; Albert Paintsil; Kofi Bonney; William Ampofo; Gerd Pluschke; Dorothy Yeboah-Manu
Journal:  Am J Trop Med Hyg       Date:  2015-06-08       Impact factor: 2.345

Review 8.  Buruli ulcer: reductive evolution enhances pathogenicity of Mycobacterium ulcerans.

Authors:  Caroline Demangel; Timothy P Stinear; Stewart T Cole
Journal:  Nat Rev Microbiol       Date:  2009-01       Impact factor: 60.633

9.  Mycolactone-mediated inhibition of tumor necrosis factor production by macrophages infected with Mycobacterium ulcerans has implications for the control of infection.

Authors:  Egídio Torrado; Sarojini Adusumilli; Alexandra G Fraga; Pamela L C Small; António G Castro; Jorge Pedrosa
Journal:  Infect Immun       Date:  2007-05-21       Impact factor: 3.441

10.  Dynamics of the cytokine response to Mycobacterium ulcerans during antibiotic treatment for M. ulcerans disease (Buruli ulcer) in humans.

Authors:  F S Sarfo; R O Phillips; E Ampadu; F Sarpong; E Adentwe; M Wansbrough-Jones
Journal:  Clin Vaccine Immunol       Date:  2008-11-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.